Medindia

X

Sigma-Aldrich Corporation's 2nd Quarter 2008 Earnings Conference Call

Friday, July 11, 2008 General News J E 4
Advertisement
ST. LOUIS, July 11 Sigma-Aldrich Corporation(Nasdaq: SIAL), will hold its quarterly conference call to discuss secondquarter results on Wednesday, July 23, 2008, at 11:00 a.m. Eastern Time (10a.m. Central Time).

This call is being webcast by Thomson/CCBN and can be accessed atSigma-Aldrich's Web site at http://www.sigma-aldrich.com .

The webcast is also being distributed through the Thomson StreetEventsNetwork to both institutional and individual investors. Individual investorscan listen to the call at http://www.fulldisclosure.com , Thomson/CCBN'sindividual investor portal, powered by StreetEvents. Institutional investorscan access the call via Thomson's password-protected event management site,StreetEvents (http://www.streetevents.com).

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and HighTechnology company. Our biochemical and organic chemical products and kitsare used in scientific and genomic research, biotechnology, pharmaceuticaldevelopment, the diagnosis of disease and as key components in pharmaceuticaland other high technology manufacturing. We have customers in life sciencecompanies, university and government institutions, hospitals and in industry.Over one million scientists and technologists use our products. Sigma-Aldrichoperates in 36 countries and has over 7,900 employees providing excellentservice worldwide. We are committed to the success of our Customers,Employees and Shareholders through leadership in Life Science, High Technologyand Service. For more information about Sigma-Aldrich, please visit ouraward-winning web site at http://www.sigma-aldrich.com .

Media Contact

Debbie Bockius, 314.286.8015

debbie.bockius@sial.com

SOURCE Sigma-Aldrich Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Long-Term Pegylated Interferon Alfa-2b Therapy in ...
S
Silence Therapeutics Announces Successful Oppositi...